rmtОбщая реаниматологияGeneral Reanimatology1813-97792411-7110FSBI "SRIGR" RAMS10.15360/1813-9779-2016-6-82-107rmt-1564Research ArticleОБЗОРЫ И КРАТКИЕ СООБЩЕНИЯREVIEWS & SHORT COMMUNICATIONSСорбенты для экстракорпорального удаления токсических веществ и молекул с нежелательной биологической активностью (обзор)Sorbents for Extracorporeal Removal of Toxic Substances and Molecules with Adverse Biological Activity (Review)МорозовА. С.MorozovA. S.

107045, г. Москва, Луков пер., д. 4, оф. 8

4 Lukov Side Str., Of. 8, Moscow 107045

morozovas84@gmail.comБессоновИ. В.BessonovI. V.

107045, г. Москва, Луков пер., д. 4, оф. 8

4 Lukov Side Str., Of. 8, Moscow 107045

НуждинаА. В.NuzhdinaA. V.

105005, г. Москва, 2-я Бауманская ул., д. 5, стр. 1

5 Baumanskaya 2nd Str., Build. 1, Moscow 105005

ПисаревВ. М.PisarevV. M.

107031, г. Москва, ул. Петровка, д. 25, стр. 2

25 Petrovka Str., Build. 2, Moscow 107031

АО Перспективные медицинские технологииРоссияJSC “Advanced Medical Technologies”Russian FederationМосковский государственный технический университет им. Н. Э. БауманаРоссияBauman Moscow State Technical UniversityRussian FederationНИИ общей реаниматологии им. В. А. НеговскогоРоссияV. A. Negovsky Research Institute of General ReanimatologyRussian Federation20162501201712682107Copyright © Морозов А.С., Бессонов И.В., Нуждина А.В., Писарев В.М., 20172017Морозов А.С., Бессонов И.В., Нуждина А.В., Писарев В.М.Morozov A.S., Bessonov I.V., Nuzhdina A.V., Pisarev V.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.reanimatology.com/rmt/article/view/1564

В обзоре рассмотрены сорбенты и медицинские изделия на их основе, применяемые в клинической практике для экстракорпоральной детоксикации с помощью процедуры гемосорбции. Представлены данные исследователей, свидетельствующие об эффективности такого подхода с целью удаления бактериальных эндотоксинов, липопротеинов низкой плотности, билирубина, а также при лечении аутоиммунных заболеваний. Основное внимание уделено применению гемосорбции при лечении тяжелого сепсиса и септического шока. Обосновывается необходимость разработки и применения новых «мультимодальных» сорбентов, сочетающих свойства как «селективных», так и «неселективных» сорбентов. В обзоре приведены сведения о клинической эффективности гемосорбции и молекулярном взаимодействии сорбента с циркулирующими молекулами, патогенетически значимыми для развития критических состояний и тяжелых заболеваний. Библиография — 137 ссылок.

The review devoted to sorbents and sorbentbased medical devices used in clinical practice for extracorporeal detoxification using a hemoperfusion technique. Clinical data have confirmed the effectiveness of this approach for removal of bacterial endotoxins, lowdensity lipoproteins, and bilirubin. Other studies demonstrated successful application of sorbents to treat autoimmune diseases. Special attention is paid to hemoperfusion in as a possible treatment for severe sepsis and septic shock. The review justifies importance of development and application of novel multimodal sorbents, which combine both properties of selective and nonselective sorbents. The review discusses clinical efficacy of hemoperfusion and key molecular interactions between the sorbent and circulating molecules pathogenetically relevant to developing critical illness and severe diseases. The reference list: 137.

гемосорбентплазмосорбентсорбирующий полимерный материалсепсисэкстракор поральная терапияsorbentplasmasorbenthemoperfusionabsorbing polymer materialsepsisextracorporeal therapyReferencesToshiaki I. Hemoadsorption in critical care. Ther. Apher. 2002; 6 (3): 189–192. http://dx.doi.org/10.1046/j.15260968.2002.00430.x.PMID: 12109941Toshiaki I. Hemoadsorption in critical care. Ther. Apher. 2002; 6 (3): 189– 192. http://dx.doi.org/10.1046/j.15260968.2002.00430.x. PMID: 12109941Winchester J.F., Ronco C., Brady J.A., Clemmer J., Muller T.E., Davankov V., Tsyurupa M., Pavlova L., Pavlov M., Levin N.W. History of sorbents in uremia. Contrib. Nephrol. 2001; 133: 131–139. http://dx.doi.org/10.1159/000060120. PMID: 11477746Winchester J.F., Ronco C., Brady J.A., Clemmer J., Muller T.E., Davankov V., Tsyurupa M., Pavlova L., Pavlov M., Levin N.W. History of sorbents in uremia. Contrib. Nephrol. 2001; 133: 131–139. http://dx.doi.org/10.1159/000060120. PMID: 11477746Ash S.R. Extracorporeal blood detoxification by sorbents in treatment of hepatic encephalopathy. Adv. Ren. Replace Ther. 2002; 9 (1): 3–18. http://dx.doi.org/10.1053/jarr.2002.30474. PMID: 11927902Ash S.R. Extracorporeal blood detoxification by sorbents in treatment of hepatic encephalopathy. Adv. Ren. Replace Ther. 2002; 9 (1): 3–18. http://dx.doi.org/10.1053/jarr.2002.30474. PMID: 11927902Winchester J.F., Salsberg J.A. Sorbents in the treatment of renal failure. Minerva Urol. Nefrol. 2004; 56 (3): 215–221. PMID: 15467500Winchester J.F., Salsberg J.A. Sorbents in the treatment of renal failure. Minerva Urol. Nefrol. 2004; 56 (3): 215–221. PMID: 15467500Shoji H., Tani T., Hanasawa K., Kodama M. Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application. Ther. Apher. 1998; 2 (1): 3–12. http://dx.doi.org/10.1111/j.17449987.1998.tb00066.x.PMID: 10227782Shoji H., Tani T., Hanasawa K., Kodama M. Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application. Ther. Apher. 1998; 2 (1): 3–12. http://dx.doi.org/10.1111/j.17449987.1998.tb00066.x.PMID: 10227782Ronco C. Endotoxin removal: history of a mission. Blood Purif. 2014; 37 (Suppl 1): 5–8. http://dx.doi.org/10.1159/000356831. PMID: 24457488Ronco C. Endotoxin removal: history of a mission. Blood Purif. 2014; 37 (Suppl 1): 5–8. http://dx.doi.org/10.1159/000356831. PMID: 24457488Ash S.R. Hemodiabsorption in treatment of acute hepatic failure and chronic cirrhosis with ascites. Artif. Organs. 1994; 18 (5): 355–362. http://dx.doi.org/10.1111/j.15251594.1994.tb02216.x. PMID: 8037609Ash S.R. Hemodiabsorption in treatment of acute hepatic failure and chronic cirrhosis with ascites. Artif. Organs. 1994; 18 (5): 355–362. http://dx.doi.org/10.1111/j.15251594.1994.tb02216.x. PMID: 8037609Mitzner S.R., Stange J., Klammt S., Peszynski P., Schmidt R., Noldge Schomburg G. Extracorporeal detoxification using molecular adsorbent recirculating system for critically ill patients with liver failure. J. Am. Soc. Nephrol. 2001; 12 (Suppl 17): S75–S82. PMID: 11251037Mitzner S.R., Stange J., Klammt S., Peszynski P., Schmidt R., Noldge Schomburg G. Extracorporeal detoxification using molecular adsorbent recirculating system for critically ill patients with liver failure. J. Am. Soc. Nephrol. 2001; 12 (Suppl 17): S75–S82. PMID: 11251037Winchester J.F., Ronco C., Brady J.A., Cowgill L.D., Salsberg J., Yousha E., Choquette M., Albright R., Clemmer J., Davankov V., Tsyurupa M., Pavlova L., Pavlov M., Cohen G., HörlW., Gotch F., Levin N.W. The next step from highflux dialysis: application of sorbent technology. Blood Purif. 2002; 20 (1): 81–86. http://dx.doi.org/10.1159/000046989. PMID: 11803163Winchester J.F., Ronco C., Brady J.A., Cowgill L.D., Salsberg J., Yousha E., Choquette M., Albright R., Clemmer J., Davankov V., Tsyurupa M., Pavlova L., Pavlov M., Cohen G., HörlW., Gotch F., Levin N.W. The next step from highflux dialysis: application of sorbent technology. Blood Purif. 2002; 20 (1): 81–86. http://dx.doi.org/10.1159/000046989.PMID: 11803163Geiger H., Klepper J., Lux P., Heidland A. Biochemical assessment and clinical evaluation of a bilirubin adsorbent column (BR350) in critically ill patients with intractable jaundice. Int. J. Artif. Organs. 1992; 15 (1): 35–39. PMID: 1551726Geiger H., Klepper J., Lux P., Heidland A. Biochemical assessment and clinical evaluation of a bilirubin adsorbent column (BR350) in critically ill patients with intractable jaundice. Int. J. Artif. Organs. 1992; 15 (1): 35–39. PMID: 1551726Tabei K., Akai Y., Takeda S., Homma S., Kusano E., Asano Y. Application of plasma perfusion in hepaticfailure. Biomater. Artif. Cells Immobilization Biotechnol. 1991; 19 (1): 193–201. http://dx.doi.org/10.3109/10731199109117826. PMID: 1751670Tabei K., Akai Y., Takeda S., Homma S., Kusano E., Asano Y. Application of plasma perfusion in hepaticfailure. Biomater. Artif. Cells Immobilization Biotechnol. 1991; 19 (1): 193–201. http://dx.doi.org/10.3109/10731199109117826. PMID: 1751670Mikhalovsky S.V. Microparticles for hemoperfusion and extracorporeal therapy. In: Arshady R. (ed.). Microspheres, microcapsules and liposomes. The MML Series, vol. 2: medical & biotechnology applications. London: Citus Books; 1999: 133–169.Mikhalovsky S.V. Microparticles for hemoperfusion and extracorporeal therapy. In: Arshady R. (ed.). Microspheres, microcapsules and liposomes. The MML Series, vol. 2: medical & biotechnology applications. London: Citus Books; 1999: 133–169.Gordon A., Lewin A.J., Maxwell M.H., Roberts M. Current status of dialysate regeneration for the treatment of chronic uremia. In: Chang T.M.S. (ed.). Artificial kidney, artificial liver, and artificial cells. N.Y.: Plenum Press; 1978: 23–32. http://dx.doi.org/10.1007/9781468424782_4Gordon A., Lewin A.J., Maxwell M.H., Roberts M. Current status of dialysate regeneration for the treatment of chronic uremia. In: Chang T.M.S. (ed.). Artificial kidney, artificial liver, and artificial cells. N.Y.: Plenum Press; 1978: 23–32. http://dx.doi.org/10.1007/9781468424782_4Sangster B., van Heijst A.N.P., Sixma J.J. The influence of hemoperfusion on hemostasis and cellular constituents of the blood in the treatment of intoxications — a comparative study of 3 types of columns (Haemocol, Amberlite XAD4, Gambro Adsorba 300oC). Arch. Toxicol. 1981; 47 (4): 269–278. http://dx.doi.org/10.1007/bf00332393. PMID: 7271453Sangster B., van Heijst A.N.P., Sixma J.J. The influence of hemoperfusion on hemostasis and cellular constituents of the blood in the treatment of intoxications — a comparative study of 3 types of columns (Haemocol, Amberlite XAD4, Gambro Adsorba 300oC). Arch. Toxicol. 1981; 47 (4): 269–278. http://dx.doi.org/10.1007/bf00332393.PMID: 7271453Clark W.T., III. Biocompatible hemoperfusion system. United States patent US4048064 (USA). 1977 Sept 13.Clark W.T., III. Biocompatible hemoperfusion system. United States patent US4048064 (USA). 1977 Sept 13.Cerulli N., La Greca G., Laville M., Palla R., Ramello A., Ghezzi P.M., Fouque D., Pizzarelli F., Schena F.P., Tetta C., Buades J., Camussi G., David S., Hoerl W., Triolo G., Maggiore U., Chiarulli G., Losurdo N., Petrarulo F., Sacchetti A., Pallotta G., Dagostino F., Del Mastro G., Sasdelli M., Mura C., Bongiorno P., Grill A., Varvara M., Carabellese S., Laraia E., Rizzi R., Mancini A., Losappio R., Maiorca R., Movilli E., Scolari F., Fiorini F., Imperatore P., Ranieri F., Bozzi M., Cuzzola R., De Min A., Specchio A., Bonomini M., Cuonzo M.T., Di Bari M., Dogliani M., Fidelio T., Ghezzi P.M., Meinero S., Canepari G., Surian M., Bonforte G., Rivera R., Sangalli L., Broccoli R., Maggiore Q., Pizzarelli F., Cavatorta F., Zollo A., Mastrangelo F., De Blasi V., Alfonso L., Usberti M., Rondina M., Laville M., Fouque D., Combarnous F., Basile C., Giordano R., Palla R., Betti G., Lopez T., Casino F., Ponticelli C., Valenti G., Ambroso G., Como G., di Belgioioso G.B., Bertoli S., Buzzi L., Albertazzi A., Lucchi L., Virgilio M., Giancaspro V., Pastore G., Conversano A., Testa A., Malcangi U., Reina E., Rusconi L., Meterangelis A., Amato M., Campolo G., Giachino G., Chiappero F., Carozzi S., Schelotto C., Sanna A., Stallone C., Aucella F., Ramello A., Marangella M., Vitale C., Quarello F., Formica M., Gastaldi L., Frattini G.M., Ervo R., Mij M., Baroni A., Borzumati M., Maschio G., Tessitore N., Loschiavo C., La Greca G., Brendolan A., Sessa A., Conte F., Ancarani E., Costantini S., Galliani M., Lorenz M., Robba C. The effect of hemodiafiltration with online endogenous reinfusion (online HFR) on anemia: design of a European, open, randomised, multicentre trial. J. Nephrol. 2000; 13 (1): 34–42. PMID: 10720212Cerulli N., La Greca G., Laville M., Palla R., Ramello A., Ghezzi P.M., Fouque D., Pizzarelli F., Schena F.P., Tetta C., Buades J., Camussi G., David S., Hoerl W., Triolo G., Maggiore U., Chiarulli G., Losurdo N., Petrarulo F., Sacchetti A., Pallotta G., Dagostino F., Del Mastro G., Sasdelli M., Mura C., Bongiorno P., Grill A., Varvara M., Carabellese S., Laraia E., Rizzi R., Mancini A., Losappio R., Maiorca R., Movilli E., Scolari F., Fiorini F., Imperatore P., Ranieri F., Bozzi M., Cuzzola R., De Min A., Specchio A., Bonomini M., Cuonzo M.T., Di Bari M., Dogliani M., Fidelio T., Ghezzi P.M., Meinero S., Canepari G., Surian M., Bonforte G., Rivera R., Sangalli L., Broccoli R., Maggiore Q., Pizzarelli F., Cavatorta F., Zollo A., Mastrangelo F., De Blasi V., Alfonso L., Usberti M., Rondina M., Laville M., Fouque D., Combarnous F., Basile C., Giordano R., Palla R., Betti G., Lopez T., Casino F., Ponticelli C., Valenti G., Ambroso G., Como G., di Belgioioso G.B., Bertoli S., Buzzi L., Albertazzi A., Lucchi L., Virgilio M., Giancaspro V., Pastore G., Conversano A., Testa A., Malcangi U., Reina E., Rusconi L., Meterangelis A., Amato M., Campolo G., Giachino G., Chiappero F., Carozzi S., Schelotto C., Sanna A., Stallone C., Aucella F., Ramello A., Marangella M., Vitale C., Quarello F., Formica M., Gastaldi L., Frattini G.M., Ervo R., Mij M., Baroni A., Borzumati M., Maschio G., Tessitore N., Loschiavo C., La Greca G., Brendolan A., Sessa A., Conte F., Ancarani E., Costantini S., Galliani M., Lorenz M., Robba C. The effect of hemodiafiltration with online endogenous reinfusion (online HFR) on anemia: design of a European, open, randomised, multicentre trial. J. Nephrol. 2000; 13 (1): 34–42. PMID: 10720212Falkenhagen D., Strobl W., Hartmann T., Schrefl A., Linsberger I., Kellner K.H., Aussenegg Z., Leitner A. Patient safety technology extracorporeal for microadsorbent systems in blood purification. Artif. Organs. 2002; 26 (2): 84–90. http://dx.doi.org/10.1046/j.15251594.2002.06884.x. PMID: 11879234Falkenhagen D., Strobl W., Hartmann T., Schrefl A., Linsberger I., Kellner K.H., Aussenegg Z., Leitner A. Patient safety technology extracorporeal for microadsorbent systems in blood purification. Artif. Organs. 2002; 26 (2): 84–90. http://dx.doi.org/10.1046/j.15251594.2002.06884.x. PMID: 11879234Yu Y.T., Chen C.Z. Advances of adsorbents for hemoperfusion in China. Biomater. Artif. Cells Artif. Organs. 1990; 18 (4): 499–505. http://dx.doi.org/10.3109/10731199009119624. PMID: 2285812Yu Y.T., Chen C.Z. Advances of adsorbents for hemoperfusion in China. Biomater. Artif. Cells Artif. Organs. 1990; 18 (4): 499–505. http://dx.doi.org/10.3109/10731199009119624. PMID: 2285812Bansal R.C., Donnet J.B., Stoeckli F. (eds.). Active carbon. N.Y.: Marcel Dekker; 1988: 482.Bansal R.C., Donnet J.B., Stoeckli F. (eds.). Active carbon. N.Y.: Marcel Dekker; 1988: 482.Cipoletti J.J. Resin technology in medicine. In: Cipoletti J.J., Kunin R., Meyer F. Sorbents and their clinical applications. N.Y.: Academic Press; 1980: 221–248.Cipoletti J.J. Resin technology in medicine. In: Cipoletti J.J., Kunin R., Meyer F. Sorbents and their clinical applications. N.Y.: Academic Press; 1980: 221–248.Афанасьева O.K., Алтынова Е.В., Болдырев А.Г., Соколов А.А., Адамова И.Ю., Покровский С.H. Сравнительный анализ эффективности и специфичности разных сорбентов для афереза липопротеидов низкой плотности. Бюл. эксперим. биологии и медицины. 2006; 142 (11): 532–536. http://dx.doi.org/10.1007/s1051700604254. PMID: 17415469Afanas’eva O.I., Altynova E.V., Boldyrev A.G., Sokolov A.A., Adamova I.Y., Pokrovskii S.N. Sravnitelnyi analiz effektivnosti i spetsifichnosti raznykh sorbentov dlya afereza lipoproteidov nizkoi plotnosti. [Comparative analysis of efficiency and specificity of various sorbents for apheresis of lowdensity lipoproteins]. Byulleten Eksperimentalnoi Biologii i Meditsiny. 2006; 142 (5): 587– 590. http://dx.doi.org/10.1007/s1051700604254. PMID: 17415469. [In Russ.]Yokoyama S., Hayashi R., Satani M., Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholes terolemia. Arteriosclerosis. 1985; 5 (6): 613–622. http://dx.doi.org/10.1161/01.atv.5.6.613. PMID: 3865648Yokoyama S., Hayashi R., Satani M., Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholes terolemia. Arteriosclerosis. 1985; 5 (6): 613–622. http://dx.doi.org/10.1161/01.atv.5.6.613. PMID: 3865648Koll R.A. LDLTherasorb immunoadsorption for the treatment of severe hypercholesterolemia refractory to conventional therapy. Ther. Apher. 1998; 2 (2): 142–146. http://dx.doi.org/10.1111/j.17449987.1998.tb00092.x. PMID: 10225716Koll R.A. LDLTherasorb immunoadsorption for the treatment of severe hypercholesterolemia refractory to conventional therapy. Ther. Apher. 1998; 2 (2): 142–146. http://dx.doi.org/10.1111/j.17449987.1998.tb00092.x. PMID: 10225716Bosch T. Recent advances in therapeutic apheresis. J. Artif. Organs. 2003; 6 (l): 1–8. http://dx.doi.org/10.1007/s100470300000. PMID: 14598117Bosch T. Recent advances in therapeutic apheresis. J. Artif. Organs. 2003; 6 (l): 1–8. http://dx.doi.org/10.1007/s100470300000. PMID: 14598117Thompson G.R. LDL apheresis. Atherosclerosis. 2003; 167 (1): 1–13. http://dx.doi.org/10.1016/s00219150(02)002514. PMID: 12618263Thompson G.R. LDL apheresis. Atherosclerosis. 2003; 167 (1): 1–13. http://dx.doi.org/10.1016/s00219150(02)002514. PMID: 12618263NewsomDavis J. Autoimmunity in neuromuscular disease. Ann. N. Y. Acad. Sci. 1988; 540: 25–38. http://dx.doi.org/10.1111/j.17496632.1988.tb27048.x. PMID: 2849891NewsomDavis J. Autoimmunity in neuromuscular disease. Ann. N. Y. Acad. Sci. 1988; 540: 25–38. http://dx.doi.org/10.1111/j.17496632.1988.tb27048.x. PMID: 2849891Bradl M., Lassmann H. Neurologic autoimmunity: mechanisms revealed by animal models. Handb. Clin. Neurol. 2016; 133: 121–143. http://dx.doi.org/10.1016/B9780444634320.000086. PMID: 27112675Bradl M., Lassmann H. Neurologic autoimmunity: mechanisms revealed by animal models. Handb. Clin. Neurol. 2016; 133: 121–143. http://dx.doi.org/10.1016/B9780444634320.000086. PMID: 27112675Gilhus N.E., Skeie G.O., Romi F., Lazaridis K., Zisimopoulou P., Tzartos S. Myasthenia gravis — autoantibody characteristics and their implica tions for therapy. Nat. Rev. Neurol. 2016; 12 (5): 259–268. http://dx.doi.org/10.1038/nrneurol.2016.44. PMID: 27103470Gilhus N.E., Skeie G.O., Romi F., Lazaridis K., Zisimopoulou P., Tzartos S. Myasthenia gravis — autoantibody characteristics and their implications for therapy. Nat. Rev. Neurol. 2016; 12 (5): 259–268. http://dx.doi.org/10.1038/nrneurol.2016.44. PMID: 27103470Von Thun Und HohensteinBlaul N., Bell K., Pfeiffer N., Grus F.H. Autoimmune aspects in glaucoma. Eur. J. Pharmacol. 2016; 787: 105–118. http://dx.doi.org/10.1016/j.ejphar.2016.04.031. PMID: 27090926Von Thun Und HohensteinBlaul N., Bell K., Pfeiffer N., Grus F.H. Autoimmune aspects in glaucoma. Eur. J. Pharmacol. 2016; 787: 105–118. http://dx.doi.org/10.1016/j.ejphar.2016.04.031. PMID: 27090926Lally L., Sammaritano L.R. Vasculitis in antiphospholipid syndrome. Rheum. Dis. Clin. North Am. 2015; 41 (1): 109–123. http://dx.doi.org/10.1016/j.rdc.2014.09.009. PMID: 25399943Lally L., Sammaritano L.R. Vasculitis in antiphospholipid syndrome. Rheum. Dis. Clin. North Am. 2015; 41 (1): 109–123. http://dx.doi.org/10.1016/j.rdc.2014.09.009. PMID: 25399943Conigliaro P., Chimenti M.S., Triggianese P., Sunzini F., Novelli L., Perricone C., Perricone R. Autoantibodies in inflammatory arthritis. Autoimmun. Rev. 2016; 15 (7): 673–683. http://dx.doi.org/10.1016/j.autrev.2016.03.003. PMID: 26970491Conigliaro P., Chimenti M.S., Triggianese P., Sunzini F., Novelli L., Perricone C., Perricone R. Autoantibodies in inflammatory arthritis. Autoimmun. Rev. 2016; 15 (7): 673–683. http://dx.doi.org/10.1016/j.autrev.2016.03.003. PMID: 26970491Sueoka A. Present status of apheresis technologies, part 3: adsorbent. Ther. Apher. 1997; 1 (3): 271–283. http://dx.doi.org/10.1111/j.17449987.1997.tb00150.x. PMID: 10225751Sueoka A. Present status of apheresis technologies, part 3: adsorbent. Ther. Apher. 1997; 1 (3): 271–283. http://dx.doi.org/10.1111/j.17449987.1997.tb00150.x. PMID: 10225751Hashimoto H., Tsuda H., Kanai Y., Kobayashi S., Hirose S., Shinoura H., Yokohari R., Kinoshita M., Aotsuka S., Yamada H., Takahashi K., Yoshiyama S., Miyamoto T. Selective removal of antiDNA and anticar diolipin antibodies by adsorbent plasmapheresis using dextran sulfate columns in patients with systemic lupus erythematosus. J. Rheumatol. 1991; 18 (4): 545–551. PMID: 2066947Hashimoto H., Tsuda H., Kanai Y., Kobayashi S., Hirose S., Shinoura H., Yokohari R., Kinoshita M., Aotsuka S., Yamada H., Takahashi K., Yoshiyama S., Miyamoto T. Selective removal of antiDNA and anticar diolipin antibodies by adsorbent plasmapheresis using dextran sulfate columns in patients with systemic lupus erythematosus. J. Rheumatol. 1991; 18 (4): 545–551. PMID: 2066947Wiesenhuter C., Irish B., Bertram J. Treatment of patients with refractory rheumatoid arthritis with extracorporeal proteinA immunoadsorption column: a pilot trial. J. Rheumatol. 1994; 21 (5): 804–812. PMID: 8064718Wiesenhuter C., Irish B., Bertram J. Treatment of patients with refractory rheumatoid arthritis with extracorporeal proteinA immunoadsorption column: a pilot trial. J. Rheumatol. 1994; 21 (5): 804–812. PMID: 8064718Falson D.T., LaValley M.P., Baldassare A.R., Block J.A., Caldwell J.R., Cannon G.W., Deal C., Evance S., Fleischmann R., Gendreau R.M., Harris E.R., Matteson E.L., Roth S.H., Schumacher H.R., Weisman M.H., Furst D.E. The Prosorba column for treatment of refractory rheumatoid arthritis: A randomized, doubleblind, shamcontrolled trial. Arthritis. Rheum. 1999; 42 (10): 2153–2159. http://dx.doi.org/10.1002/15290131(199910)42:10<2153::aidanr16>3.0.co;2w. PMID: 10524687Falson D.T., LaValley M.P., Baldassare A.R., Block J.A., Caldwell J.R., Cannon G.W., Deal C., Evance S., Fleischmann R., Gendreau R.M., Harris E.R., Matteson E.L., Roth S.H., Schumacher H.R., Weisman M.H., Furst D.E. The Prosorba column for treatment of refractory rheumatoid arthritis: A randomized, doubleblind, shamcontrolled trial. Arthritis. Rheum. 1999; 42 (10): 2153–2159. http://dx.doi.org/10.1002/15290131(199910)42:10<2153::aidanr16>3.0.co;2w. PMID: 10524687Braun N., Risler T. Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther. Apher. 1999; 3 (3): 240– 245. http://dx.doi.org/10.1046/j.15260968.1999.00155.x. PMID: 10427622Braun N., Risler T. Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther. Apher. 1999; 3 (3): 240–245. http://dx.doi.org/10.1046/j.15260968.1999.00155.x. PMID: 10427622Oka K., Nakaji S., Tanihara M., Takakura K., Takamori M. Development of specific immunoadsorbent containing immobilized synthetic peptide of acetylcholine receptor for treatment of myasthenia gravis. Jpn. J. Artif. Organs. 1993; 22: 194–197.Oka K., Nakaji S., Tanihara M., Takakura K., Takamori M. Development of specific immunoadsorbent containing immobilized synthetic peptide of acetylcholine receptor for treatment of myasthenia gravis. Jpn. J. Artif. Organs. 1993; 22: 194–197.Nakaji S., Oka K., Tanihara M., Takakura K., Takamori M. Development of a specific immunoadsorbent containing immobilized synthetic peptide of acetylcholine receptor for treatment of myasthenia gravis. 1993. Ther. Apher. 2000; 4 (2): 124–126. http://dx.doi.org/10.1046/j.15260968.2000.004002124.x. PMID: 10805430Nakaji S., Oka K., Tanihara M., Takakura K., Takamori M. Development of a specific immunoadsorbent containing immobilized synthetic peptide of acetylcholine receptor for treatment of myasthenia gravis. 1993. Ther. Apher. 2000; 4 (2): 124– 126. http://dx.doi.org/10.1046/j.15260968.2000.004002124.x. PMID: 10805430Koll R.A. IgTherasorb immunoadsorption for selective removal of human immunoglobulin diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins. Ther. Apher. 1998; 2 (2): 147–152. http://dx.doi.org/10.1111/j.17449987.1998.tb00093.x. PMID: 10225717Koll R.A. IgTherasorb immunoadsorption for selective removal of human immunoglobulin diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins. Ther. Apher. 1998; 2 (2): 147–152. http://dx.doi.org/10.1111/j.17449987.1998.tb00093.x. PMID: 10225717Kutsuki H., Takata S., Yamamoto K., Tani N. Therapeutic selective adsorption of antiDNA antibody using dextran sulfate cellulose column (Selesorb) for the treatment of systemic lupus erythematosus. Ther. Apher. 1998; 2: 18–24. http://dx.doi.org/10.1111/j.17449987.1998.tb00068.x. PMID: 10227784Kutsuki H., Takata S., Yamamoto K., Tani N. Therapeutic selective adsorption of antiDNA antibody using dextran sulfate cellulose column (Selesorb) for the treatment of systemic lupus erythematosus. Ther. Apher. 1998; 2: 18–24. http://dx.doi.org/10.1111/j.17449987.1998.tb00068.x. PMID: 10227784Pokrovsky S., Kuznetsova Yu.V., Afanasieva O.I., Zvezdkin P.V., Adamova I. Yu., Konovalov G.A. Clinical experience of immunoadsorption with ‘Ig Adsopak’ columns. Ther. Apher. Dial. 2005; 9 (5): A38. http://dx.doi.org/10.1111/j.17449987.2005.00324_4.xPokrovsky S., Kuznetsova Yu.V., Afanasieva O.I., Zvezdkin P.V., Adamova I. Yu., Konovalov G.A. Clinical experience of immunoadsorption with ‘Ig Adsopak’ columns. Ther. Apher. Dial. 2005; 9 (5): A38. http://dx.doi.org/10.1111/j.17449987.2005.00324_4.xZahir F., Rabbani G., Khan R.H., Rizvi S.J., Jamal M.S., Abuzenadah A.M. The pharmacological features of bilirubin: the question of the century. Cell Mol. Biol. Lett. 2015; 20 (3): 418–447. http://dx.doi.org/10.1515/cmble20150012. PMID: 26208389Zahir F., Rabbani G., Khan R.H., Rizvi S.J., Jamal M.S., Abuzenadah A.M. The pharmacological features of bilirubin: the question of the century. Cell Mol. Biol. Lett. 2015; 20 (3): 418–447. http://dx.doi.org/10.1515/cmble20150012. PMID: 26208389Qaisiya M., Brischetto C., Jašprová J., Vitek L., Tiribelli C., Bellarosa C. Bilirubininduced ER stress contributes to the inflammatory response and apoptosis in neuronal cells. Arch. Toxicol. 2016; [Epub ahead of print]. http://dx.doi.org/10.1007/s0020401618353. PMID: 27578021Qaisiya M., Brischetto C., Jašprová J., Vitek L., Tiribelli C., Bellarosa C. Bilirubininduced ER stress contributes to the inflammatory response and apoptosis in neuronal cells. Arch. Toxicol. 2016; [Epub ahead of print]. http://dx.doi.org/10.1007/s0020401618353. PMID: 27578021Ahlfors C. Plasma bilirubin binding and bilirubin neurotoxicity. Dev. Med. Child Neurol. 2016; [Epub ahead of print]. http://dx.doi.org/10.1111/dmcn.13303. PMID: 27786370Ahlfors C. Plasma bilirubin binding and bilirubin neurotoxicity. Dev. Med. Child Neurol. 2016; [Epub ahead of print]. http://dx.doi.org/10.1111/dmcn.13303. PMID: 27786370Riordan S.M., Bittel D.C., Le Pichon J.B., Gazzin S., Tiribelli C., Watchko J.F., Wennberg R.P., Shapiro S.M. A hypothesis for using pathway genetic load analysis for understanding complex outcomes in bilirubin encephalopathy. Front Neurosci. 2016; 10: 376. http://dx.doi.org/10.3389/fnins.2016.00376. PMID: 27587993Riordan S.M., Bittel D.C., Le Pichon J.B., Gazzin S., Tiribelli C., Watchko J.F., Wennberg R.P., Shapiro S.M. A hypothesis for using pathway genetic load analysis for understanding complex outcomes in bilirubin encephalopathy. Front Neurosci. 2016; 10: 376. http://dx.doi.org/10.3389/fnins.2016.00376. PMID: 27587993Watchko J.F. Bilirubininduced neurotoxicity in the preterm neonate. Clin. Perinatol. 2016; 43 (2): 297–311. http://dx.doi.org/10.1016/j.clp.2016.01.007. PMID: 27235209Watchko J.F. Bilirubininduced neurotoxicity in the preterm neonate. Clin. Perinatol. 2016; 43 (2): 297–311. http://dx.doi.org/10.1016/j.clp.2016.01.007. PMID: 27235209Bhutani V.K., Wong R.J., Stevenson D.K. Hyperbilirubinemia in preterm neonates. Clin. Perinatol. 2016; 43 (2): 215–232. http://dx.doi.org/10.1016/j.clp.2016.01.001. PMID: 27235203Bhutani V.K., Wong R.J., Stevenson D.K. Hyperbilirubinemia in preterm neonates. Clin. Perinatol. 2016; 43 (2): 215–232. http://dx.doi.org/10.1016/j.clp.2016.01.001. PMID: 27235203Amin S.B., Wang H., Laroia N., Orlando M. Unbound bilirubin and auditory neuropathy spectrum disorder in late preterm and term infants with severe jaundice. J. Pediatr. 2016; 173: 84–89. http://dx.doi.org/10.1016/j.jpeds.2016.02.024. PMID: 26952116Amin S.B., Wang H., Laroia N., Orlando M. Unbound bilirubin and auditory neuropathy spectrum disorder in late preterm and term infants with severe jaundice. J. Pediatr. 2016; 173: 84–89. http://dx.doi.org/10.1016/j.jpeds.2016.02.024. PMID: 26952116Wusthoff C.J., Loe I.M. Impact of bilirubininduced neurologic dysfunction on neurodevelopmental outcomes. Semin. Fetal. Neonatal. Med. 2015; 20 (1): 52–57. http://dx.doi.org/10.1016/j.siny.2014.12.003. PMID: 25585889Wusthoff C.J., Loe I.M. Impact of bilirubininduced neurologic dysfunction on neurodevelopmental outcomes. Semin. Fetal. Neonatal. Med. 2015; 20 (1): 52–57. http://dx.doi.org/10.1016/j.siny.2014.12.003. PMID: 25585889Olusanya B.O. Societal impact of bilirubininduced hearing impairment in resourcelimited nations. Semin. Fetal. Neonatal. Med. 2015; 20 (1): 58–63. http://dx.doi.org/10.1016/j.siny.2014.12.009. PMID:25573775Olusanya B.O. Societal impact of bilirubininduced hearing impairment in resourcelimited nations. Semin. Fetal. Neonatal. Med. 2015; 20 (1): 58–63. http://dx.doi.org/10.1016/j.siny.2014.12.009. PMID:25573775Gazzin S., Vitek L., Watchko J., Shapiro S.M., Tiribelli C. A novel perspective on the biology of bilirubin in health and disease. Trends Mol. Med. 2016; 22 (9): 758–768. http://dx.doi.org/10.1016/j.molmed.2016.07.004. PMID: 27515064Gazzin S., Vitek L., Watchko J., Shapiro S.M., Tiribelli C. A novel perspective on the biology of bilirubin in health and disease. Trends Mol. Med. 2016; 22 (9): 758–768. http://dx.doi.org/10.1016/j.molmed.2016.07.004. PMID: 27515064Tan H.K. Molecular Adsorbent Recirculating System (MARS). Ann. Acad. Med. Singapore. 2004; 33 (3): 329–335. PMID: 15175774Tan H.K. Molecular Adsorbent Recirculating System (MARS). Ann. Acad. Med. Singapore. 2004; 33 (3): 329–335. PMID: 15175774Collins K.L., Roberts E.A., Adeli K., Bohn D., Harvey E.A. Single pass albumin dialysis (SPAD) in fulminant Wilsonian liver failure: a case report. Pediatr. Nephrol. 2008; 23 (6): 1013–1016. http://dx.doi.org/10.1007/s004670080761x. PMID: 18299897Collins K.L., Roberts E.A., Adeli K., Bohn D., Harvey E.A. Single pass albumin dialysis (SPAD) in fulminant Wilsonian liver failure: a case report. Pediatr. Nephrol. 2008; 23 (6): 1013–1016. http://dx.doi.org/10.1007/s004670080761x. PMID: 18299897Mitzner S., Klammt S., Stange J., Schmidt R. Albumin regeneration in liver supportcomparison of different methods. Ther. Apher. Dial. 2006; 10 (2): 108–117. http://dx.doi.org/10.1111/j.17449987.2006.00351.x.PMID: 16684211Mitzner S., Klammt S., Stange J., Schmidt R. Albumin regeneration in liver supportcomparison of different methods. Ther. Apher. Dial. 2006; 10 (2): 108–117. http://dx.doi.org/10.1111/j.17449987.2006.00351.x. PMID: 16684211Takenaka Y. Bilirubin adsorbent column for plasma perfusion. Ther. Apher. 1998; 2 (2): 129–133. http://dx.doi.org/10.1111/j.17449987.1998.tb00090.x. PMID: 10225714Takenaka Y. Bilirubin adsorbent column for plasma perfusion. Ther. Apher. 1998; 2 (2): 129–133. http://dx.doi.org/10.1111/j.17449987.1998.tb00090.x. PMID: 10225714Nakaji S., Hayashi N. Bilirubin adsorption column Medisorba BL300. Ther. Apher. Dial. 2003; 7 (1): 98–103. http://dx.doi.org/10.1046/j.15260968.2003.00007.x. PMID: 12921123Nakaji S., Hayashi N. Bilirubin adsorption column Medisorba BL300. Ther. Apher. Dial. 2003; 7 (1): 98–103. http://dx.doi.org/10.1046/j.15260968.2003.00007.x. PMID: 12921123Stegmayr B.G. Plasmapheresis in severe sepsis or septic shock. Blood Purif. 1996; 14 (1): 94–101. http://dx.doi.org/10.1159/000170250. PMID: 8718572Stegmayr B.G. Plasmapheresis in severe sepsis or septic shock. Blood Purif. 1996; 14 (1): 94–101. http://dx.doi.org/10.1159/000170250. PMID: 8718572Stegmayr B.G. Is there a future for adsorption techniques in sepsis? Blood Purif. 2000; 18 (2): 149–155. http://dx.doi.org/10.1159/000014440. PMID: 10838475Stegmayr B.G. Is there a future for adsorption techniques in sepsis? Blood Purif. 2000; 18 (2): 149–155. http://dx.doi.org/10.1159/000014440. PMID: 10838475Rimmelé T., Kellum J.A. Clinical review: blood purification for sepsis. Crit. Care. 2011; 15 (1): 205. http://dx.doi.org/10.1186/cc9411. PMID: 21371356Rimmelé T., Kellum J.A. Clinical review: blood purification for sepsis. Crit. Care. 2011; 15 (1): 205. http://dx.doi.org/10.1186/cc9411. PMID: 21371356Воинов В.А. Эфферентная терапия критических состояний в реаниматологии. СПб.: СанктПетербургский ГМУ им. И.П.Павлова; 2013: 110.Voinov V.A. Efferentnaya terapiya kriticheskikh sostoyanii v reanima tologii. [Efferent therapy of critical states in reanimatology]. Sankt Peterburg: SanktPeterburgsky GMU Imeni I.P.Pavlova; 2013: 110. [In Russ.]Davies B., Cohen J. Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect. Dis. 2011; 11 (1): 65–71. http://dx.doi.org/10.1016/s14733099(10)702206. PMID: 21183148Davies B., Cohen J. Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect. Dis. 2011; 11 (1): 65–71. http://dx.doi.org/10.1016/s14733099(10)702206. PMID: 21183148Бажина Е.С., Никулин А.В., Хорошилов С.Е. Экстракорпоральные методы лечения абдоминального сепсиса. Общая реаниматология. 2015; 11 (5): 4566. http://dx.doi.org/10.15360/18139779201554566Bazhina E.S., Nikulin A.V., Khoroshilov S.E. Ekstrakorporalnye metody lecheniya abdominalnogo sepsisa. Obshchaya Reanimatologiya. [Extracorporeal treatments for abdominal sepsis. General Reanimatology]. 2015; 11 (5): 4566. http://dx.doi.org/10.15360/18139779201554566. [In Russ.]Ушакова Н.Д., Шевченко А.Н., Четвериков М.В., Златник Е.Ю., Зыкова Т.А. Результаты применения селективной адсорбции эндотоксина при сепсисе у онкологических больных. Общая реаниматология. 2014; 10 (6): 32–38. http://dx.doi.org/10.15360/18139779201463238Ushakova N.D., Shevchenko A.N., Chetverikov M.V., Zlatnik E.Y., Zykova T.A. Rezultaty primeneniya selektivnoi adsorbtsii endotoksina pri sepsise u onkologicheskikh bolnykh. Obshchaya Reanimatologiya. [Results of using selective endotoxin adsorption in cancer patients with sepsis. General Reanimatology]. 2014; 10 (6): 3238. http://dx.doi.org/10.15360/18139779201463238. [In Russ.]Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther. Apher. Dial. 2003; 7 (1): 108–114. http://dx.doi.org/10.1046/j.15260968.2003.00005.x.PMID:12921125Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther. Apher. Dial. 2003; 7 (1): 108–114. http://dx.doi.org/10.1046/j.15260968.2003.00005.x. PMID:12921125Nakamura T., Kawagoe Y., Suzuki T., Shoji H., Ueda Y., Koide H. Polymyxin B–immobilized fiber hemoperfusion with the PMX05R column in elderly patients suffering from septic shock. Am. J. Med. Sci. 2007; 334 (4): 244–247. http://dx.doi.org/10.1097/MAJ.0b013e3180a5e8d8. PMID: 18030179Nakamura T., Kawagoe Y., Suzuki T., Shoji H., Ueda Y., Koide H. Polymyxin B– immobilized fiber hemoperfusion with the PMX05R column in elderly patients suffering from septic shock. Am. J. Med. Sci. 2007; 334 (4): 244–247. http://dx.doi.org/10.1097/MAJ.0b013e3180a5e8d8. PMID: 18030179Toray Medical Co., Ltd. for endotoxin removal in patients with severe sepsis and septic shock. http://www.toraymedical.com/en/medical/kyusei/pdf/PMX20R.pdfToray Medical Co., Ltd. for endotoxin removal in patients with severe sepsis and septic shock. http://www.toraymedical.com/en/medical/kyusei/pdf/PMX20R.pdfKojika M., Sato N., Yaegashi Y., Suzuki Y., Suzuki K., Nakae H., Endo S. Endotoxin adsorption therapy for septic shock using polymyxin B immobilized fibers (PMX): evaluation by highsensitivity endotoxin assay and measurement of the cytokine production capacity. Ther. Apher. Dial. 2006; 10 (1): 12–18. http://dx.doi.org/10.1111/j.17449987.2006.00340.x. PMID: 16556131Kojika M., Sato N., Yaegashi Y., Suzuki Y., Suzuki K., Nakae H., Endo S. Endotoxin adsorption therapy for septic shock using polymyxin B immobilized fibers (PMX): evaluation by highsensitivity endotoxin assay and measurement of the cytokine production capacity. Ther. Apher. Dial. 2006; 10 (1): 12–18. http://dx.doi.org/10.1111/j.17449987.2006.00340.x. PMID: 16556131Shoji H., Minaga M., Sakai Y., Kunitomo T., Takeyama T., Tani T., Kodama M. Design and development of endotoxin detoxifying column PMX and its clinical application. Jpn. J. Artif. Organs. 1993; 22 (1): 204–211.Shoji H., Minaga M., Sakai Y., Kunitomo T., Takeyama T., Tani T., Kodama M. Design and development of endotoxin detoxifying column PMX and its clinical application. Jpn. J. Artif. Organs. 1993; 22 (1): 204–211.Sakai Y., Shoji H., Kobayashi T., Terada R., Sugaya H., Murakami R., Moriyama K., Minaga M., Kunitomo N., Takeyama T. New extracorpo real blood purification devices for critical care medicine under devel opment. Ther. Plasmapheresis. 1993; 12: 837–842.Sakai Y., Shoji H., Kobayashi T., Terada R., Sugaya H., Murakami R., Moriyama K., Minaga M., Kunitomo N., Takeyama T. New extracorpo real blood purification devices for critical care medicine under development. Ther. Plasmapheresis. 1993; 12: 837–842.Shimizu T., Obata T., Sonoda H., Akabori H., Tabata T., Eguchi Y., Endo Y., Tani T. The ability of endotoxin adsorption during a longer duration of direct hemoperfusion with a polymyxin Bimmobilized fiber columnin patients with septic shock. Transfus. Apher. Sci. 2013; 49 (3): 499–503. http://dx.doi.org/10.1016/j.transci.2013.04.042. PMID: 23683501Shimizu T., Obata T., Sonoda H., Akabori H., Tabata T., Eguchi Y., Endo Y., Tani T. The ability of endotoxin adsorption during a longer duration of direct hemoperfusion with a polymyxin Bimmobilized fiber column in patients with septic shock. Transfus. Apher. Sci. 2013; 49 (3): 499–503. http://dx.doi.org/10.1016/j.transci.2013.04.042. PMID: 23683501Jaber B.L., Barrett T.W., Cendoroglo Neto M., Sundaram S., King A.J., Pereira B.J. Endotoxin removal by polymyxinB immobilized polystyrenederivative fibers during in vitro hemoperfusion of 10% human plasma. ASAIO J. 1998; 44 (1): 54–61. http://dx.doi.org/10.1097/0000248019980100000012. PMID: 9466502Jaber B.L., Barrett T.W., Cendoroglo Neto M., Sundaram S., King A.J., Pereira B.J. Endotoxin removal by polymyxinB immobilized polystyrenederivative fibers during in vitro hemoperfusion of 10% human plasma. ASAIO J. 1998; 44 (1): 54–61. http://dx.doi.org/10.1097/0000248019980100000012. PMID: 9466502Tani T., Hanasawa K., Kodama M., Imaizumi H., Yonekawa M., Saito M., Ikeda T., Yagi Y., Takayama K., Amano I., Shimaoka H., Ohta M., Okahisa T., Koga N., Fujita N., Yamasa H. Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor1 activities in septic patients. World J. Surg. 2001; 25 (5): 660–668. http://dx.doi.org/10.1007/s002680020028. PMID: 11396436Tani T., Hanasawa K., Kodama M., Imaizumi H., Yonekawa M., Saito M., Ikeda T., Yagi Y., Takayama K., Amano I., Shimaoka H., Ohta M., Okahisa T., Koga N., Fujita N., Yamasa H. Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor1 activities in septic patients. World J. Surg. 2001; 25 (5): 660–668. http://dx.doi.org/10.1007/s002680020028. PMID: 11396436Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Maeda S., Yamagishi S. Suppression of highmobility group box1 and receptor for advanced glycation endproduct axis by polymyxin B–immobilized fiber hemop erfusion in septic shock patients. J. Crit. Care. 2011; 26 (6): 546– 549. http://dx.doi.org/10.1016/j.jcrc.2010.11.010. PMID: 21273029Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Maeda S., Yamagishi S. Suppression of highmobility group box1 and receptor for advanced glycation endproduct axis by polymyxin B–immobilized fiber hemoperfusion in septic shock patients. J. Crit. Care. 2011; 26 (6): 546–549. http://dx.doi.org/10.1016/j.jcrc.2010.11.010. PMID: 21273029Oishi K., MimuraKimura Y., Miyasho T., Aoe K., Ogata Y., Katayama H., Murata Y., Ueoka H., Matsumoto T., Mimura Y. Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine. 2013; 61 (1): 84–89. http://dx.doi.org/10.1016/j.cyto.2012.08.032. PMID: 23021430Oishi K., MimuraKimura Y., Miyasho T., Aoe K., Ogata Y., Katayama H., Murata Y., Ueoka H., Matsumoto T., Mimura Y. Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine. 2013; 61 (1): 84–89. http://dx.doi.org/10.1016/j.cyto.2012.08.032. PMID: 23021430Shimizu T., Hanasawa K., Sato K., Umeki M., Koga N., Naganuma T., Sato S., Shimonishi T., Ikeda T., Matsuno N., Ono S., Saitoh H., Satoh K., Otani Y., Endo Y., Eguchi Y., Tani T.; PMX Treatment Study Group in Septic Patients with Colorectal Perforation. The clinical significance of serum procalcitonin levels following direct hemoperfusion with polymyxin Bimmobilized fiber column in septic patients with colorectal perforation. Eur. Surg. Res. 2009; 42 (2): 109–117. http://dx.doi.org/10.1159/000187169. PMID: 19122457Shimizu T., Hanasawa K., Sato K., Umeki M., Koga N., Naganuma T., Sato S., Shimonishi T., Ikeda T., Matsuno N., Ono S., Saitoh H., Satoh K., Otani Y., Endo Y., Eguchi Y., Tani T.; PMX Treatment Study Group in Septic Patients with Colorectal Perforation. The clinical significance of serum procalcitonin levels following direct hemoperfusion with polymyxin Bimmobilized fiber column in septic patients with colorectal perforation. Eur. Surg. Res. 2009; 42 (2): 109–117. http://dx.doi.org/10.1159/000187169. PMID: 19122457Hanasawa K., Tani T., Oka T., Yoshioka T., Endo Y., Horisawa M., Nakane Y., Kodama M., Teramoto K., Nishiumi S. A new treatment for endotoxemia with direct hemoperfusion by polymyxin immobilized fiber. Ther. Apher. 2000; 4 (2): 142–145. http://dx.doi.org/10.1046/j.15260968.2000.004002142.x. PMID: 10805433Hanasawa K., Tani T., Oka T., Yoshioka T., Endo Y., Horisawa M., Nakane Y., Kodama M., Teramoto K., Nishiumi S. A new treatment for endotoxemia with direct hemoperfusion by polymyxin immobilized fiber. Ther. Apher. 2000; 4 (2): 142–145. http://dx.doi.org/10.1046/j.15260968.2000.004002142.x. PMID: 10805433Tani T., Hanasawa K., Endo Y., Yoshioka T., Kodama M., Kaneko M., Uchiyama Y., Akizawa T., Takahasi K., Sugai K. Therapeutic apheresis for septic patients with organ dysfunction: hemoperfusion using a polymyxin B immobilized column. Artif. Organs. 1998; 22 (12): 1038– 1044. http://dx.doi.org/10.1046/j.15251594.1998.06086.x. PMID: 9876096Tani T., Hanasawa K., Endo Y., Yoshioka T., Kodama M., Kaneko M., Uchiyama Y., Akizawa T., Takahasi K., Sugai K. Therapeutic apheresis for septic patients with organ dysfunction: hemoperfusion using a polymyxin B immobilized column. Artif. Organs. 1998; 22 (12): 1038–1044. http://dx.doi.org/10.1046/j.15251594.1998.06086.x. PMID: 9876096Kodama M., Hanasawa K., Tani T. Blood purification for critical care medicine: endotoxin adsorption. Ther. Apher. 1997; 1 (3): 224–227. http://dx.doi.org/10.1111/j.17449987.1997.tb00142.x. PMID: 10225743Kodama M., Hanasawa K., Tani T. Blood purification for critical care medicine: endotoxin adsorption. Ther. Apher. 1997; 1 (3): 224–227. http://dx.doi.org/10.1111/j.17449987.1997.tb00142.x. PMID: 10225743Cruz D.N., Perazella M.A., Bellomo R., de Cal M., Polanco N., Corradi V., Lentini P., Nalesso F., Ueno T., Ranieri V.M., Ronco C. Effectiveness of polymyxin Bimmobilized fiber column in sepsis: a systematic review. Crit. Care. 2007; 11 (2): R47. http://dx.doi.org/10.1186/cc5780.PMID: 17448226Cruz D.N., Perazella M.A., Bellomo R., de Cal M., Polanco N., Corradi V., Lentini P., Nalesso F., Ueno T., Ranieri V.M., Ronco C. Effectiveness of polymyxin Bimmobilized fiber column in sepsis: a systematic review. Crit. Care. 2007; 11 (2): R47. http://dx.doi.org/10.1186/cc5780.PMID: 17448226Nakamura T., Ebihara I., Shoji H., Ushiyama C., Suzuki S., Koide H. Treatment with polymyxin Bimmobilized fiber reduces platelet activation in septic shock patients: decrease in plasma levels of soluble P selectin, platelet factor4 and betathromboglobulin. Inflamm. Res. 1999; 48 (4): 171–175. http://dx.doi.org/10.1007/s000110050442. PMID: 10344466Nakamura T., Ebihara I., Shoji H., Ushiyama C., Suzuki S., Koide H. Treatment with polymyxin Bimmobilized fiber reduces platelet activation in septic shock patients: decrease in plasma levels of soluble P selectin, platelet factor4 and betathromboglobulin. Inflamm. Res. 1999; 48 (4): 171–175. http://dx.doi.org/10.1007/s000110050442.PMID: 10344466Nemoto H., Nakamoto H., Okada H., Sugahara S., Moriwaki K., Arai M., Kanno Y., Suzuki H. Newly developed polymyxin Bimmobilized fibers improve the survival of patients with sepsis. Blood Purif. 2001; 19 (4): 361–369. http://dx.doi.org/10.1159/000046966. PMID: 11574732Nemoto H., Nakamoto H., Okada H., Sugahara S., Moriwaki K., Arai M., Kanno Y., Suzuki H. Newly developed polymyxin Bimmobilized fibers improve the survival of patients with sepsis. Blood Purif. 2001; 19 (4): 361–369. http://dx.doi.org/10.1159/000046966. PMID: 11574732Nakamura T., Ushiyama C., Suzuki Y., Shoji H., Shimada N., Koide H. Hemoperfusion with polymyxinB immobilized fiber for urinary albumin excretion in septic patients with trauma. ASAIO J. 2002; 48 (3): 244–248. http://dx.doi.org/10.1097/0000248020020500000008. PMID: 12058997Nakamura T., Ushiyama C., Suzuki Y., Shoji H., Shimada N., Koide H. Hemoperfusion with polymyxinB immobilized fiber for urinary albumin excretion in septic patients with trauma. ASAIO J. 2002; 48 (3): 244–248. http://dx.doi.org/10.1097/0000248020020500000008. PMID: 12058997Suzuki H., Nemoto H., Nakamoto H., Okada H., Sugahara S., Kanno Y., Moriwaki K. Continuous hemodiafiltration with polymyxin B immobilized fiber is effective in patients with sepsis syndrome and acute renal failure. Ther. Apher. 2002; 6 (3): 234–240. http://dx.doi.org/10.1046/j.15260968.2002.00416.x. PMID: 12109950Suzuki H., Nemoto H., Nakamoto H., Okada H., Sugahara S., Kanno Y., Moriwaki K. Continuous hemodiafiltration with polymyxin B immobilized fiber is effective in patients with sepsis syndrome and acute renal failure. Ther. Apher. 2002; 6 (3): 234–240. http://dx.doi.org/10.1046/j.15260968.2002.00416.x. PMID: 12109950Tsushima K., Kubo K., Koizumi T., Yamamoto H., Fujimoto K., Hora K., KanNou Y. Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory. J. Clin. Apher. 2002; 17 (2): 97–102.http://dx.doi.org/10.1002/jca.10019. PMID: 12210714Tsushima K., Kubo K., Koizumi T., Yamamoto H., Fujimoto K., Hora K., KanNou Y. Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory. J. Clin. Apher. 2002; 17 (2): 97–102. http://dx.doi.org/10.1002/jca.10019. PMID: 12210714Tsugawa K., Koyanagi N., Hashizume M., Wada H., Ayukawa K., Akahoshi K., Tomikawa M., Sugimachi K. Results of endotoxin absorption after a subtotal resection of the small intestine and a right hemicolectomy for severe superior mesenteric ischemia. Hepatogastroenterology. 2002; 49 (47): 1303–1306. PMID: 12239931Tsugawa K., Koyanagi N., Hashizume M., Wada H., Ayukawa K., Akahoshi K., Tomikawa M., Sugimachi K. Results of endotoxin absorption after a subtotal resection of the small intestine and a right hemicolectomy for severe superior mesenteric ischemia. Hepatogastroenterology. 2002; 49 (47): 1303–1306. PMID: 12239931Nakamura T., Ushiyama C., Suzuki Y., Inoue T., Shoji H., Shimada N., Koide H. Combination therapy with polymyxin Bimmobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillinresistant Staphylococcus aureus. J. Hosp. Infect. 2003; 53 (1): 58–63. http://dx.doi.org/10.1053/jhin.2002.1332. PMID: 12495686Nakamura T., Ushiyama C., Suzuki Y., Inoue T., Shoji H., Shimada N., Koide H. Combination therapy with polymyxin Bimmobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillinresistant Staphylococcus aureus. J. Hosp. Infect. 2003; 53 (1): 58–63. http://dx.doi.org/10.1053/jhin.2002.1332. PMID: 12495686Nakamura T., Ushiyama C., Suzuki Y., Osada S., Inoue T., Shoji H., Hara M., Shimada N., Koide H. Hemoperfusion with polymyxinB immobilized fiber in septic patients with methicillinresistant Staphylococcus aureusassociated glomerulonephritis. Nephron. Clin. Pract. 2003; 94 (2): 33–39. http://dx.doi.org/10.1159/000071279. PMID: 12845235Nakamura T., Ushiyama C., Suzuki Y., Osada S., Inoue T., Shoji H., Hara M., Shimada N., Koide H. Hemoperfusion with polymyxinB immobilized fiber in septic patients with methicillinresistant Staphylococcus aureusassociated glomerulonephritis. Nephron. Clin. Pract. 2003; 94 (2): 33–39. http://dx.doi.org/10.1159/000071279. PMID: 12845235Nakamura T., Matsuda T., Suzuki Y., Shoji H., Koide H. Polymyxin B immobilized fiber in patients with sepsis. Dial. Transplant. 2003; 32: 602–607.Nakamura T., Matsuda T., Suzuki Y., Shoji H., Koide H. Polymyxin B immobilized fiber in patients with sepsis. Dial. Transplant. 2003; 32: 602–607.Nakamura T., Kawagoe Y., Matsuda T., Koide H. Effect of polymyxin B immobilized fiber on bone resorption in patients with sepsis. Intensive Care Med. 2004; 30 (9): 1838–1841. http://dx.doi.org/10.1007/s0013400423577. PMID: 15197430Nakamura T., Kawagoe Y., Matsuda T., Koide H. Effect of polymyxin B immobilized fiber on bone resorption in patients with sepsis. Intensive Care Med. 2004; 30 (9): 1838–1841. http://dx.doi.org/10.1007/s0013400423577. PMID: 15197430Nakamura T., Kawagoe Y., Matsuda T., Ueda Y., Koide H. Effects of polymyxin Bimmobilized fiber on urinary NacetylBglu cosaminidase in patients with severe sepsis. ASAIO J. 2004; 50 (6): 563–567. http://dx.doi.org/10.1097/01.mat.0000142875.62592.3a. PMID: 15672789Nakamura T., Kawagoe Y., Matsuda T., Ueda Y., Koide H. Effects of polymyxin Bimmobilized fiber on urinary NacetylBglu cosaminidase in patients with severe sepsis. ASAIO J. 2004; 50 (6): 563–567. http://dx.doi.org/10.1097/01.mat.0000142875.62592.3a. PMID: 15672789Ono S., Tsujinomoto H., Matsumoto A., Ikuta S., Kinoshita M., Mochizuki H. Modulation of human leukocyte antigenDR on monocytes and CD16 on granulocytes in patients with polymyxin bimmobilized fiber. Am. J. Surg. 2004; 188 (2): 150–156. http://dx.doi.org/10.1016/j.amjsurg.2003.12.067. PMID: 15249240Ono S., Tsujinomoto H., Matsumoto A., Ikuta S., Kinoshita M., Mochizuki H. Modulation of human leukocyte antigenDR on monocytes and CD16 on granulocytes in patients with polymyxin bimmobilized fiber. Am. J. Surg. 2004; 188 (2): 150–156. http://dx.doi.org/10.1016/j.amjsurg.2003.12.067. PMID: 15249240Tsujimoto H., Ono S., Hiraki S., Majima T., Kawarabayashi N., Sugasawa H., Kinoshita M., Hiraide H., Mochizuki H. Hemoperfusion with polymyxin Bimmobilized fibers reduced the number of CD16+CD14+ monocytes in patients with septic shock. J. Endotoxin. Res. 2004; 10 (4): 229–237. http://dx.doi.org/10.1179/096805104225005814. PMID: 15373966Tsujimoto H., Ono S., Hiraki S., Majima T., Kawarabayashi N., Sugasawa H., Kinoshita M., Hiraide H., Mochizuki H. Hemoperfusion with polymyxin Bimmobilized fibers reduced the number of CD16+CD14+ monocytes in patients with septic shock. J. Endotoxin. Res. 2004; 10 (4): 229–237. http://dx.doi.org/10.1179/096805104225005814. PMID: 15373966Nakamura T., Kawagoe Y., Sukuzi T., Shoji H., Ueda Y., Kobayashi N., Koide H. Changes in plasma interleukin18 by direct hemoperfusion with polymyxin Bimmobilized fiber in patients with septic shock. Blood Purif. 2005; 23 (6): 417–420. http://dx.doi.org/10.1159/000088016. PMID: 16141713Nakamura T., Kawagoe Y., Sukuzi T., Shoji H., Ueda Y., Kobayashi N., Koide H. Changes in plasma interleukin18 by direct hemoperfusion with polymyxin Bimmobilized fiber in patients with septic shock. Blood Purif. 2005; 23 (6): 417–420. http://dx.doi.org/10.1159/000088016. PMID: 16141713Vincent J.L., Laterre P.F., Cohen J., Burchardi H., Bruining H., Lerma F.A., Wittebole X., De Backer D., Brett S., Marzo D., Nakamura H., John S. A pilotcontrolled study of a polymyxin Bimmobilized hemoperfusion cartridge in patients with severe sepsis secondary to intraabdominal infection. Shock. 2005; 23 (5): 400–405. http://dx.doi.org/10.1097/01.shk.0000159930.87737.8a. PMID: 15834304Vincent J.L., Laterre P.F., Cohen J., Burchardi H., Bruining H., Lerma F.A., Wittebole X., De Backer D., Brett S., Marzo D., Nakamura H., John S. A pilotcontrolled study of a polymyxin Bimmobilized hemoperfusion cartridge in patients with severe sepsis secondary to intraabdominal infection. Shock. 2005; 23 (5): 400–405. http://dx.doi.org/10.1097/01.shk.0000159930.87737.8a. PMID: 15834304Nakamura T., Ebihara I., Shimada N., Suzuki S., Ushiyama C., Shoji H., Koide H. Effects of hemoperfusion with polymyxin Bimmobilized fibre on serum neopterin and soluble interleukin2 receptor concentrations in patients with septic shock. J. Infect. 1998; 37 (3): 241–247. http://dx.doi.org/10.1016/s01634453(98)919521. PMID: 9892527Nakamura T., Ebihara I., Shimada N., Suzuki S., Ushiyama C., Shoji H., Koide H. Effects of hemoperfusion with polymyxin Bimmobilized fibre on serum neopterin and soluble interleukin2 receptor concentrations in patients with septic shock. J. Infect. 1998; 37 (3): 241–247. http://dx.doi.org/10.1016/s01634453(98)919521. PMID: 9892527Nakamura T., Ebihara I., Shimada N., Koide H. Changes in plasma erythropoietin and interleukin6 concentrations in patients with septic shock after hemoperfusion and polymyxin Bimmobilized fiber. Intensive Care Med. 1998; 24 (12): 1272–1276. http://dx.doi.org/10.1007/s001340050761. PMID: 9885879Nakamura T., Ebihara I., Shimada N., Koide H. Changes in plasmaery thropoietin and interleukin6 concentrations in patients with septic shock after hemoperfusion and polymyxin Bimmobilized fiber. Intensive Care Med. 1998; 24 (12): 1272–1276. http://dx.doi.org/10.1007/s001340050761. PMID: 9885879Nakamura T., Kawagoe Y., Matsuda T., Shoji H., Ueda Y., Tamura N., Ebihara I., Koide H. Effect of polymyxin Bimmobilized fiber on blood metalloproteinase9 and tissue inhibitor of metalloproteinase1 levels in acute respiratory distress syndrome patients. Blood Purif. 2004; 22 (3): 256–260. http://dx.doi.org/10.1159/000078494. PMID: 15148453Nakamura T., Kawagoe Y., Matsuda T., Shoji H., Ueda Y., Tamura N., Ebihara I., Koide H. Effect of polymyxin Bimmobilized fiber on blood metalloproteinase9 and tissue inhibitor of metalloproteinase1 levels in acute respiratory distress syndrome patients. Blood Purif. 2004; 22 (3): 256–260. http://dx.doi.org/10.1159/000078494. PMID: 15148453Shimada N., Nakamura T., Takayashi Y., Tanaka A., Shoji H., Sekizuka K., Ebihara I., Koide H. Effects of polymyxin Bimmobilized fiber on serum phosphate concentrations in patients with sepsis. Nephron. 2000; 86 (3): 359–360. http://dx.doi.org/10.1159/000045800. PMID: 11096302Shimada N., Nakamura T., Takayashi Y., Tanaka A., Shoji H., Sekizuka K., Ebihara I., Koide H. Effects of polymyxin Bimmobilized fiber on serum phosphate concentrations in patients with sepsis. Nephron. 2000; 86 (3): 359–360. http://dx.doi.org/10.1159/000045800. PMID: 11096302Tojimbara T., Sato S., Nakajima I., Fuchinoue S., Akiba T., Teraoka S. Polymyxin Bimmobilized fiber hemoperfusion after emergency surgery in patients with chronic renal failure. Ther. Apher. Dial. 2004; 8 (4): 286–292. http://dx.doi.org/10.1111/j.15260968.2004.00166.x.PMID: 15274679Tojimbara T., Sato S., Nakajima I., Fuchinoue S., Akiba T., Teraoka S. Polymyxin Bimmobilized fiber hemoperfusion after emergency surgery in patients with chronic renal failure. Ther. Apher. Dial. 2004; 8 (4): 286–292. http://dx.doi.org/10.1111/j.15260968.2004.00166.x. PMID: 15274679Ueno T., Sugino M., Nemoto H., Shoji H., Kakita A., Watanabe M. Effect over time of endotoxin adsorption therapy in sepsis. Ther. Apher. Dial. 2005; 9 (2): 128–136. http://dx.doi.org/10.1111/j.17749987.2005.00230.x. PMID: 15828924Ueno T., Sugino M., Nemoto H., Shoji H., Kakita A., Watanabe M. Effect over time of endotoxin adsorption therapy in sepsis. Ther. Apher. Dial. 2005; 9 (2): 128– 136. http://dx.doi.org/10.1111/j.17749987.2005.00230.x. PMID: 15828924Uriu K., Osajima A., Hiroshige K., Watanabe H., Aibara K., Inada Y., Segawa K., Anai H., Takagi I., Ito A., Kamochi M., Kaizu K. Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin Bimmobilized fiber ameliorates systemic circulatory distur bance in patients with septic shock. Am. J. Kidney Dis. 2002; 39 (5): 937–947. http://dx.doi.org/10.1053/ajkd.2002.32767. PMID: 11979337Uriu K., Osajima A., Hiroshige K., Watanabe H., Aibara K., Inada Y., Segawa K., Anai H., Takagi I., Ito A., Kamochi M., Kaizu K. Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin Bimmobilized fiber ameliorates systemic circulatory disturbance in patients with septic shock. Am. J. Kidney Dis. 2002; 39 (5): 937–947. http://dx.doi.org/10.1053/ajkd.2002.32767. PMID: 11979337Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., Peterson E., Tomlanovich M.; Early GoalDirected Therapy Collaborative Group. Early goaldirected therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 2001; 345 (19): 1368–1377. http://dx.doi.org/10.1056/nejmoa010307. PMID: 11794169Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., Peterson E., Tomlanovich M.; Early GoalDirected Therapy Collaborative Group. Early goaldirected therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 2001; 345 (19): 1368–1377. http://dx.doi.org/10.1056/nejmoa010307. PMID: 11794169Ikeda T., Ikeda K., Nagura M., Taniuchi H., Matsushita M., Kiuchi S., Kuroki Y., Suzuki K., Matsuno N. Clinical evaluation of PMXDHP for hypercytokinemia caused by septic multiple organ failure. Ther. Apher. Dial. 2004; 8 (4): 293–298. http://dx.doi.org/10.1111/j.15260968.2004.00167.x. PMID: 15274680Ikeda T., Ikeda K., Nagura M., Taniuchi H., Matsushita M., Kiuchi S., Kuroki Y., Suzuki K., Matsuno N. Clinical evaluation of PMXDHP for hypercytokinemia caused by septic multiple organ failure. Ther. Apher. Dial. 2004; 8 (4): 293–298. http://dx.doi.org/10.1111/j.15260968.2004.00167.x. PMID: 15274680Casella G., Monti G., Terzi V., Pulici M., Ravizza A., Vesconi S. Nonconventional therapies in refractory septic shock: clinical experience with Polymyxin B. Minerva Anestesiol. 2006; 72 (1): 63–67.Casella G., Monti G., Terzi V., Pulici M., Ravizza A., Vesconi S. Nonconventional therapies in refractory septic shock: clinical experience with Polymyxin B. Minerva Anestesiol. 2006; 72 (1): 63–67.Follmann D., Elliott P., Suh I., Cutler J. Variance imputation for overviews of clinical trials with continuous response. J. Clin. Epidemiol. 1992; 45 (7): 769–773. http://dx.doi.org/10.1016/08954356(92)90054q. PMID: 1619456Follmann D., Elliott P., Suh I., Cutler J. Variance imputation for overviews of clinical trials with continuous response. J. Clin. Epidemiol1992; 45 (7): 769–773. http://dx.doi.org/10.1016/08954356(92)90054q. PMID: 1619456Kushi H., Miki T., Okamoto K., Nakahara J., Saito T., Tanjoh K. Early haemoperfusion with an immobilized polymyxin B fiber column elimi nates humoral mediators and improves pulmonary oxygenation. Crit. Care. 2005; 9 (6): R653–R661. http://dx.doi.org/10.1186/cc3815.PMID: 16280061Kushi H., Miki T., Okamoto K., Nakahara J., Saito T., Tanjoh K. Early haemoperfusion with an immobilized polymyxin B fiber column elimi nates humoral mediators and improves pulmonary oxygenation. Crit. Care. 2005; 9 (6): R653–R661. http://dx.doi.org/10.1186/cc3815.PMID: 16280061Cruz D.N., Antonelli M., Fumagalli R., Foltran F., Brienza N., Donati A., Malcangi V., Petrini F., Volta G., Bobbio Pallavicini F.M., Rottoli F., Giunta F., Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009; 301 (23): 2445–2452. http://dx.doi.org/10.1001/jama.2009.856. PMID: 19531784Cruz D.N., Antonelli M., Fumagalli R., Foltran F., Brienza N., Donati A., Malcangi V., Petrini F., Volta G., Bobbio Pallavicini F.M., Rottoli F., Giunta F., Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009; 301 (23): 2445–2452. http://dx.doi.org/10.1001/jama.2009.856. PMID: 19531784Vincent J.L. Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA. 2009; 302 (18): 1967–1968. http://dx.doi.org/10.1001/jama.2009.1606. PMID: 19903915Vincent J.L. Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA. 2009; 302 (18): 1967–1968. http://dx.doi.org/10.1001/jama.2009.1606. PMID: 19903915Amaral A.C. Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA. 2009; 302 (18): 1968–1970. http://dx.doi.org/10.1001/jama.2009.1607. PMID: 19903914Amaral A.C. Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA. 2009; 302 (18): 1968–1970. http://dx.doi.org/10.1001/jama.2009.1607. PMID: 19903914Kase Y., Obata T., Okamoto Y., Iwai K., Saito K., Yokoyama K., Takinami M., Tanifuji Y. Removal of 2arachidonylglycerol by direct hemoperfusion therapy with polymyxin B immobilized fibers benefits patients with septic shock. Ther. Apher. Dial. 2008; 12 (5): 374–380. http://dx.doi.org/10.1111/j.17449987.2008.00612.x. PMID: 18937720Kase Y., Obata T., Okamoto Y., Iwai K., Saito K., Yokoyama K., Takinami M., Tanifuji Y. Removal of 2arachidonylglycerol by direct hemoperfusion therapy with polymyxin B immobilized fibers benefits patients with septic shock. Ther. Apher. Dial. 2008; 12 (5): 374–380. http://dx.doi.org/10.1111/j.17449987.2008.00612.x. PMID: 18937720Cantaluppi V., Assenzio B., Pasero D., Romanazzi G.M., Pacitti A., Lanfranco G., Puntorieri V., Martin E.L., Mascia L., Monti G., Casella G., Segoloni G.P., Camussi G., Ranieri V.M. PolymyxinB hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med. 2008; 34 (9): 1638–1645. http://dx.doi.org/10.1007/s0013400811246. PMID: 18463848Cantaluppi V., Assenzio B., Pasero D., Romanazzi G.M., Pacitti A., Lanfranco G., Puntorieri V., Martin E.L., Mascia L., Monti G., Casella G., Segoloni G.P., Camussi G., Ranieri V.M. PolymyxinB hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med. 2008; 34 (9): 1638–1645. http://dx.doi.org/10.1007/s0013400811246.PMID: 18463848Kohro S., Imaizumi H., Yamakage M., Masuda Y., Namiki A., Asai Y., Maruyama I. Anandamide absorption by direct hemoperfusion with polymixin Bimmobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis. J. Anesth. 2006; 20 (1): 11–16. http://dx.doi.org/10.1007/s0054000503665. PMID: 16421670Kohro S., Imaizumi H., Yamakage M., Masuda Y., Namiki A., Asai Y., Maruyama I. Anandamide absorption by direct hemoperfusion with polymixin Bimmobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis. J. Anesth. 2006; 20 (1): 11–16. http://dx.doi.org/10.1007/s0054000503665. PMID: 16421670Matsuno N., Ikeda T., Ikeda K., Hama K., Iwamoto H., Uchiyama M., Kozaki K., Narumi Y., Kikuchi K., Degawa H., Nagao T. Changes of cytokines in direct endotoxin adsorption treatment on postoperative multiple organ failure. Ther. Apher. 2001; 5 (1): 36–39. http://dx.doi.org/10.1046/j.15260968.2001.005001036.x. PMID: 11258608Matsuno N., Ikeda T., Ikeda K., Hama K., Iwamoto H., Uchiyama M., Kozaki K., Narumi Y., Kikuchi K., Degawa H., Nagao T. Changes of cytokines in direct endotoxin adsorption treatment on postoperative multiple organ failure. Ther. Apher. 2001; 5 (1): 36–39. http://dx.doi.org/10.1046/j.15260968.2001.005001036.x. PMID: 11258608Novelli G., Ferretti G., Poli L., Pretagostini R., Ruberto F., Perrella S.M., Levi Sandri G.B., Morabito V., Berloco P.B. Clinical results of treatment of postsurgical endotoxinmediated sepsis with polymyxinB direct hemo perfusion. Transplant. Proc. 2010; 42 (4): 1021–1024. http://dx.doi.org/10.1016/j.transproceed.2010.03.056. PMID: 20534214Novelli G., Ferretti G., Poli L., Pretagostini R., Ruberto F., Perrella S.M., Levi Sandri G.B., Morabito V., Berloco P.B. Clinical results of treatment of postsurgical endotoxinmediated sepsis with polymyxinB direct hemoperfusion. Transplant. Proc. 2010; 42 (4): 1021–1024. http://dx.doi.org/10.1016/j.transproceed.2010.03.056. PMID: 20534214Mori M., Onaka T., Yonezawa A., Kitagawa T., Sasaki Y., Imada K. Direct hemoperfusion using polymyxinB immobilized fiber for severe septic patients with hematological disorders: a singlecenter analysis. J. Infect. Chemother. 2014; 20 (4): 282–284. http://dx.doi.org/10.1016/j.jiac.2013.12.008. PMID: 24485325Mori M., Onaka T., Yonezawa A., Kitagawa T., Sasaki Y., Imada K. Direct hemoperfusion using polymyxinB immobilized fiber for severe septic patients with hematological disorders: a singlecenter analysis. J. Infect. Chemother. 2014; 20 (4): 282–284. http://dx.doi.org/10.1016/j.jiac.2013.12.008. PMID: 24485325Mitaka C., Fujiwara N., Yamamoto M., Toyofuku T., Haraguchi G., Tomita M. Polymyxin Bimmobilized fiber column hemoperfusion removes endotoxin throughout a 24hour treatment period. J. Crit. Care. 2014; 29 (5): 728–732. http://dx.doi.org/10.1016/j.jcrc.2014.03.031.PMID: 24798345Mitaka C., Fujiwara N., Yamamoto M., Toyofuku T., Haraguchi G., Tomita M. Polymyxin Bimmobilized fiber column hemoperfusion removes endotoxin throughout a 24hour treatment period. J. Crit. Care. 2014; 29 (5): 728–732. http://dx.doi.org/10.1016/j.jcrc.2014.03.031. PMID: 24798345Klein D.J., Foster D., Schorr C.A., Kazempour K., Walker P.M., Dellinger R.P. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized con trolled trial. Trials. 2014; 15: 218. http://dx.doi.org/10.1186/1745621515218. PMID: 24916483Klein D.J., Foster D., Schorr C.A., Kazempour K., Walker P.M., Dellinger R.P. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. Trials. 2014; 15: 218. http://dx.doi.org/10.1186/1745621515218. PMID: 24916483Cutuli S.L., Artigas A., Fumagalli R., Monti G., Ranieri V.M., Ronco C., Antonelli M.; EUPHAS 2 Collaborative Group. PolymyxinB hemoper fusion in septic patients: analysis of a multicenter registry. Ann. Intensive Care. 2016; 6 (1): 77. http://dx.doi.org/10.1186/s1361301601789. PMID: 27502196Cutuli S.L., Artigas A., Fumagalli R., Monti G., Ranieri V.M., Ronco C., Antonelli M.; EUPHAS 2 Collaborative Group. PolymyxinB hemoper fusion in septic patients: analysis of a multicenter registry. Ann. Intensive Care. 2016; 6 (1): 77. http://dx.doi.org/10.1186/s1361301601789. PMID: 27502196Quenot J.P., Binquet C., Kara F., Martinet O., Ganster F., Navellou J.C., Castelain V., Barraud D., Cousson J., Louis G., Perez P., Kuteifan K., Noirot A., Badie J., Mezher C., Lessire H., Pavon A. The epidemiology of septic shock in French intensive care units: the prospective multicen ter cohort EPISS study. Crit. Care. 2013; 17 (2): R65. http://dx.doi.org/10.1186/cc12598. PMID: 23561510Quenot J.P., Binquet C., Kara F., Martinet O., Ganster F., Navellou J.C., Castelain V., Barraud D., Cousson J., Louis G., Perez P., Kuteifan K., Noirot A., Badie J., Mezher C., Lessire H., Pavon A. The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study. Crit. Care. 2013; 17 (2): R65. http://dx.doi.org/10.1186/cc12598. PMID: 23561510Phua J., Koh Y., Du B., Tang Y.Q., Divatia J.V., Tan C.C., Gomersall C.D., Faruq M.O., Shrestha B.R., Gia Binh N., Arabi Y.M., Salahuddin N., Wahyuprajitno B., Tu M.L., Wahab A.Y., Hameed A.A., Nishimura M., Procyshyn M., Chan Y.H.; MOSAICS Study Group. Management of severe sepsis in patients admitted to Asian intensive care units: prospective cohort study. BMJ. 2011; 342: d3245. http://dx.doi.org/10.1136/bmj.d3245. PMID: 21669950Phua J., Koh Y., Du B., Tang Y.Q., Divatia J.V., Tan C.C., Gomersall C.D., Faruq M.O., Shrestha B.R., Gia Binh N., Arabi Y.M., Salahuddin N., Wahyuprajitno B., Tu M.L., Wahab A.Y., Hameed A.A., Nishimura M., Procyshyn M., Chan Y.H.; MOSAICS Study Group. Management of severe sepsis in patients admitted to Asian intensive care units: prospective cohort study. BMJ. 2011; 342: d3245. http://dx.doi.org/10.1136/bmj.d3245. PMID: 21669950Chihara S., MasudaY., Tatsumi H., Nakano K., Shimada T., Murohashi T., Yamakage M. Early induction of direct hemoperfusion with a polymyx inB immobilized column is associated with amelioration of hemody namic derangement and mortality in patients with septic shock. J. Artif. Organs. 2016; [Epub ahead of print]. http://dx.doi.org/10.1007/s1004701609229. PMID: 27469940Chihara S., MasudaY., Tatsumi H., Nakano K., Shimada T., Murohashi T., Yamakage M. Early induction of direct hemoperfusion with a polymyx inB immobilized column is associated with amelioration of hemodynamic derangement and mortality in patients with septic shock. J. Artif. Organs. 2016; [Epub ahead of print]. http://dx.doi.org/10.1007/s1004701609229. PMID: 27469940Kulabukhov V. Use of an endotoxin adsorber in the treatment of severe abdominal sepsis. Acta Anaesthesiol. Scand. 2008; 52 (7): 1024–1025. http://dx.doi.org/10.1111/j.13996576.2008.01677.x. PMID: 18494849Kulabukhov V. Use of an endotoxin adsorber in the treatment of severe abdominal sepsis. Acta Anaesthesiol. Scand. 2008; 52 (7): 1024–1025. http://dx.doi.org/10.1111/j.13996576.2008.01677.x. PMID: 18494849Adamik B., Zielinski S., Smiechowicz J., Kübler A. Endotoxin elimination in patients with septic shock: an observation study. Arch. Immunol. Ther. Exp. (Warsz.). 2015; 63 (6): 475– 483. http://dx.doi.org/10.1007/s0000501503488. PMID: 26093653Adamik B., Zielinski S., Smiechowicz J., Kübler A. Endotoxin elimination in patients with septic shock: an observation study. Arch. Immunol. Ther. Exp. (Warsz.). 2015; 63 (6): 475–483. http://dx.doi.org/10.1007/s0000501503488. PMID: 26093653Mahlicli F.Y., Altinkaya S.A., Yurekli Y. Preparation and characterization of polyacrylonitrile membranes modified with polyelectrolyte deposition for separating similar sized proteins. J. Membr. Sci. 2012; 415–416 (1): 383–390. http://dx.doi.org/10.1016/j.memsci.2012.05.028Mahlicli F.Y., Altinkaya S.A., Yurekli Y. Preparation and characterization of polyacrylonitrile membranes modified with polyelectrolyte deposition for separating similar sized proteins. J. Membr. Sci. 2012; 415–416 (1): 383–390. http://dx.doi.org/10.1016/j.memsci.2012.05.028Honore P.M., Jacobs R., JoannesBoyau O., De Regt J., De Waele E., van Gorp V., Boer W., Verfaillie L., Spapen H.D. Newly designed CRRT membranes for sepsis and SIRS — a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic struc tured review. ASAIO J. 2013; 59 (2): 99–106. http://dx.doi.org/10.1097/MAT.0b013e3182816a75. PMID: 23438770Honore P.M., Jacobs R., JoannesBoyau O., De Regt J., De Waele E., van Gorp V., Boer W., Verfaillie L., Spapen H.D. Newly designed CRRT membranes for sepsis and SIRS—a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J. 2013; 59 (2): 99–106. http://dx.doi.org/10.1097/MAT.0b013e3182816a75. PMID: 23438770Mitzner S., Schneidewind J., Falkenhagen D., Loth F., Klinkmann H. Extracorporeal endotoxin removal by immobilized polyethylenimine. Artif. Organs. 1993; 17 (9): 775–781. http://dx.doi.org/10.1111/j.15251594.1993.tb00630.x. PMID: 8240070Mitzner S., Schneidewind J., Falkenhagen D., Loth F., Klinkmann H. Extracorporeal endotoxin removal by immobilized polyethylenimine. Artif. Organs. 1993; 17 (9): 775–781. http://dx.doi.org/10.1111/j.15251594.1993.tb00630.x. PMID: 8240070Shum H.P., Chan K.C., Kwan M.C., Yan W.W. Application of endotoxin and cytokine adsorption haemofilter in septic acute kidney injury due to Gramnegative bacterial infection. Hong Kong Med. J. 2013; 19 (6): 491–497. http://dx.doi.org/10.12809/hkmj133910. PMID: 23650198Shum H.P., Chan K.C., Kwan M.C., Yan W.W. Application of endotoxin and cytokine adsorption haemofilter in septic acute kidney injury due to Gramnegative bacterial infection. Hong Kong Med. J. 2013; 19 (6): 491–497. http://dx.doi.org/10.12809/hkmj133910. PMID: 23650198Bengsch S., Boos K.S., Nagel D., Seidel D., Inthorn D. Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock. 2005; 23 (6): 494–500. PMID:15897800Bengsch S., Boos K.S., Nagel D., Seidel D., Inthorn D. Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock. 2005; 23 (6): 494–500. PMID: 15897800Гапанович В.Н., Кирковский В.В., Третьяк Д.С., Голубович В.П., Куцук О.Н., Старостин А.В., Мельнова Н.И., Андреев С.В. Антилипополисахаридный гемосорбент на основе сшитого полимиксина. Сообщение 1. Военная медицина. 2012; 3: 98–99.Gapanovich V.N., Kirkovsky V.V., Tretyak D.S., Golubovich V.P., Kutsuk O.N., Starostin A.V., Melnova N.I., Andreyev S.V. Antilipopolisakharidnyi gemosorbent na osnove sshitogo polimiksina. Soobshchenie 1. [Antilipopolisakharidny haemosorbent on the basis of sewed polymyksin. Report 1]. Voennaya Meditsina. 2012; 3: 98–99. [In Russ.]Гапанович В.Н., Кирковский В.В., Третьяк Д.С., Голубович В.П., Андреев С.С., Мельнова Н.И., Жук И.Н. Антилипополисахаридный гемосорбент на основе сшитого полимиксина. Сообщение 2. Военная медицина. 2013; 2: 92–96.Gapanovich V.N., Kirkovsky V.V., Tretyak D.S., Golubovich V.P., Andreyev S.V., Melnova N.I., Zhuk I.N. Antilipopolisakharidnyi gemosorbent na osnove sshitogo polimiksina. Soobshchenie 2. [Antilipopolisakharidny haemosorbent on the basis of sewed polymyksin. Report 2]. Voennaya Meditsina. 2013; 2: 92–96. [In Russ.]Кирковский В.В., Гапанович В.Н., Третьяк Д.С., Старостин А.В., Добриянец А.И., Андреев С.В., Мельнова Н.И. Антилипополисахаридный гемосорбент на основе сшитого полимиксина. Сообщение 3. Военная медицина. 2013; 3: 97–100.Kirkovsky V.V., Gapanovich V.N., Tretyak D.S., Starostin A.V., Dobriyanets A.I., Andreyev S.V., Melnova N.I. Antilipopolisakharidnyi gemosorbent na osnove sshitogo polimiksina. Soobshchenie 3. [Antilipopolisakharidny haemosorbent on the basis of sewed polymyksin. Report 3]. Voennaya Meditsina. 2013; 3: 97–100. [In Russ.]Скворцов Н.В., Власова О.Л., Болдырев А.Г., Ларионов И.В. Оценка эффективности сорбента Сфероцелл С80 в динамическом режиме. Научнотехнические ведомости СПбГПУ. Физикоматематические науки. 2015; 2: 91–98.Skvortsov N.V., Vlasova O.L., Boldyrev A.G., Larionov I.V. Otsenka effektivnosti sorbenta Sferotsell C80 v dinamicheskom rezhime. [Evaluation of the effectiveness of the sorbent Sferotsell C80 in dynamic mode]. NauchnoTekhnicheskie Vedomosti SanktPeterburgskogo GPU. Fiziko Matematicheskie Nauki. 2015; 2: 91–98. [In Russ.]Скворцов Н.В., Самойлов В.О., Ларионов И.В., Болдырев А.Г. Эффективный сорбент для элиминации эндотоксина в биопрепаратах генноинженерного генеза и биологических жидкостях. Научно технические ведомости СПбГПУ. Физикоматематические науки. 2013; 3: 177–181.Skvortsov N.V., Samoilov V.O., Larionov I.V., Boldyrev A.G. Effektivnyi sorbent dlya eliminatsii endotoksina v biopreparatakh gennoinzhen ernogo geneza i biologicheskikh zhidkostyakh. [An effective sorbent for elimination endotoxin in biological products of genetically engineered genesis and biological liquids]. NauchnoTekhnicheskie Vedomosti SanktPeterburgskogo GPU. FizikoMatematicheskie Nauki. 2013; 3 (177): 177–181. [In Russ.] 134. http://toxipak.ru/column/about/http://toxipak.ru/column/about/Payen D.M., Guilhot J., Launey Y., Lukaszewicz A.C., Kaaki M., Veber B., Pottecher J., JoannesBoyau O., MartinLefevre L., Jabaudon M., Mimoz O., Coudroy R., Ferrandière M., Kipnis E., Vela C., Chevallier S., Mallat J., Robert R.; ABDOMIX Group. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015; 41 (6): 975–984. http://dx.doi.org/10.1007/s001340153751z. PMID: 25862039Payen D.M., Guilhot J., Launey Y., Lukaszewicz A.C., Kaaki M., Veber B., Pottecher J., JoannesBoyau O., MartinLefevre L., Jabaudon M., Mimoz O., Coudroy R., Ferrandière M., Kipnis E., Vela C., Chevallier S., Mallat J., Robert R.; ABDOMIX Group. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015; 41 (6): 975–984. http://dx.doi.org/10.1007/s001340153751z. PMID: 25862039Sugiura M., Mitaka C., Haraguchi G., Tomita M., Inase N. Polymyxin B immobilized fiber column hemoperfusion mainly helps to constrict peripheral blood vessels in treatment for septic shock. J. Intensive Care. 2015; 3 (1): 14. http://dx.doi.org/10.1186/s4056001500809.PMID: 25866644Sugiura M., Mitaka C., Haraguchi G., Tomita M., Inase N. Polymyxin B immobilized fiber column hemoperfusion mainly helps to constrict peripheral blood vessels in treatment for septic shock. J. Intensive Care. 2015; 3 (1): 14. http://dx.doi.org/10.1186/s4056001500809. PMID: 25866644Davankov V., Pavlova L., Tsyurupa M., Brady J., Balsamo M., Yousha E. Polymeric adsorbent for removing toxic proteins from blood of patients with kidney failure. J. Chromatogr. B. Biomed. Sci. Appl. 2000; 739 (1): 73–80. http://dx.doi.org/10.1016/s03784347(99)00554x. PMID: 10744315Davankov V., Pavlova L., Tsyurupa M., Brady J., Balsamo M., Yousha E. Polymeric adsorbent for removing toxic proteins from blood of patients with kidney failure. J. Chromatogr. B. Biomed. Sci. Appl. 2000; 739 (1): 73–80. http://dx.doi.org/10.1016/s03784347(99)00554x. PMID: 10744315Davankov V., Pavlova L., Tsyurupa M., Brady J., Balsamo M., Yousha E. Polymeric adsorbent for removing toxic proteins from blood of patients with kidney failure. J. Chromatogr. B. Biomed. Sci. Appl. 2000; 739 (1): 73–80. http://dx.doi.org/10.1016/s03784347(99)00554x. PMID: 10744315

The authors declare that there are no conflicts of interest present.